Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Background Following a clinical evaluation of deferasirox (Exjade (R)) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, i...
Saved in:
Main Authors: | Cappellini, M.D., Porter, J., El-Beshlawy, A., Li, C.K., Seymour, J.F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J.W., Chan, L.L., Lin, K.H., Rose, C., Taher, A., Thein, S.L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Investigators, EPIC Study |
---|---|
Format: | Article |
Published: |
2010
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/14887/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
by: Pennell, D.J., et al.
Published: (2010) -
Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010) -
Insights into relationships between serum ferritin and liver iron concentration trends during 12 months of iron chelation therapy with deferasirox - a post-hoc analysis from the epic study
by: Porter, J.B., et al.
Published: (2014) -
Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C
by: Cappellini, M.D., et al.
Published: (2010) -
Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years
by: Pennell, D., et al.
Published: (2010)